Cutler Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-1,700
Closed -$10K 4978
2022
Q4
$10K Buy
+1,700
New +$110K ﹤0.01% 2735
2022
Q3
Sell
-1,000
Closed -$1K 5708
2022
Q2
$1K Buy
+1,000
New +$63.6K ﹤0.01% 4815
2022
Q1
Sell
-4,600
Closed -$22K 6279
2021
Q4
$22K Sell
4,600
-20,400
-82% -$3.17M ﹤0.01% 3061
2021
Q3
$67K Buy
+25,000
New +$4.02M ﹤0.01% 2270
2021
Q1
Sell
-8,100
Closed -$1K 6487
2020
Q4
$1K Sell
8,100
-500
-6% -$108K ﹤0.01% 4658
2020
Q3
$49K Sell
8,600
-2,200
-20% -$301K ﹤0.01% 1817
2020
Q2
$74K Sell
10,800
-5,600
-34% -$543K ﹤0.01% 1488
2020
Q1
$215K Buy
16,400
+3,900
+31% +$350K 0.01% 910
2019
Q4
$124K Buy
12,500
+5,300
+74% +$511K 0.01% 1085
2019
Q3
$271K Sell
7,200
-7,000
-49% -$657K 0.02% 564
2019
Q2
$134K Buy
14,200
+4,800
+51% +$374K 0.01% 940
2019
Q1
$15K Buy
9,400
+4,800
+104% +$327K ﹤0.01% 2247
2018
Q4
$1K Sell
4,600
-35,300
-88% -$1.41M ﹤0.01% 3762
2018
Q3
$515K Buy
39,900
+27,900
+233% +$1.55M 0.04% 455
2018
Q2
$15K Buy
+12,000
New +$453K ﹤0.01% 2410
2018
Q1
Sell
-8,500
Closed -$4K 5423
2017
Q4
$4K Sell
8,500
-5,000
-37% -$77.6K ﹤0.01% 3860
2017
Q3
$16K Buy
13,500
+5,100
+61% +$29.5K ﹤0.01% 3370
2017
Q2
$17K Sell
8,400
-7,100
-46% -$27.2K ﹤0.01% 3610
2017
Q1
$38K Buy
15,500
+3,700
+31% +$20.3K ﹤0.01% 2680
2016
Q4
$29K Buy
11,800
+10,800
+1,080% +$58.8K ﹤0.01% 3102
2016
Q3
$2K Hold
1,000
﹤0.01% 5854
2016
Q2
$3K Buy
+1,000
New +$15.9K ﹤0.01% 5470
2016
Q1
Sell
-1,200
Closed -$8K 7394
2015
Q4
$8K Buy
+1,200
New +$42.4K ﹤0.01% 4448

Other funds holding MRTX

Cutler Group's MRTX Position: Q1 2024 in Review

Cutler Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 1,500 shares — an estimated $88K sold.

Cutler Group first reported a position in MRTX in Q4 2015 and held it in 26 quarters. The position peaked at $3.6M in Q3 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Cutler Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 1,500 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $88K.
  • Cutler Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2015 and held it in 26 quarters.
  • Cutler Group's Mirati Therapeutics, Inc. Common Stock position peaked at $3.6M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.